WHO revises recommendations on hormonal contraceptive use for women at high HIV risk
29 August 2019 – WHO has revised its guidance on contraceptive use to reflect new evidence that women at high risk of HIV can use any form of reversible contraception, including progestogen-only injectables, implants and intrauterine devices, without an increased risk of HIV infection. However, as these contraceptive methods do not protect against HIV and other sexually transmitted infections, the guideline emphasizes that correct and consistent use of condoms should be used where there is a risk of STIs, including HIV.
Event-driven or daily PrEP: ANRS Prévenir study confirms that these two biomedical prevention strategies are very effective and safe
23 July 2019 – The findings from the ANRS Ipergay and Prévenir studies provided evidence for the World Health Organization to update its recommendation for oral PrEP to include an option of event-driven (also called on-demand) dosing for men who have sex with men. A technical brief detailing the evidence and considerations for event-driven PrEP implementation is being released by WHO during the 10th IAS conference in Mexico City.
WHO recommends dolutegravir as preferred HIV treatment option in all populations
22 July 2019 | Mexico City – Based on new evidence assessing benefits and risks, the WHO recommends the use of the HIV drug dolutegravir (DTG) as the preferred first-line and second-line treatment for all populations, including pregnant women and those of childbearing potential. New data from two large clinical trials comparing the efficacy and safety of DTG and efavirenz (EFV) in Africa have now expanded the evidence base. The risks of neural tube defects are significantly lower than what the initial studies may have suggested.
WHO at IAS 2019
July 2019 – WHO will hold high-level events and several key sessions at the upcoming 10th IAS Conference on HIV Science, taking place in Mexico from 21-24 July 2019. WHO will also release 11 new products and publications, present 15 scientific posters and participate in 2 press conferences.
New study finds no link between HIV infection and contraceptive methods
13 June 2019 – A large clinical research study conducted in four African countries found no significant difference in risk of HIV infection among women using one of three highly effective, reversible contraceptive methods. Published today in the Lancet, the study showed that each method had high levels of safety and effectiveness in preventing pregnancy, with all methods well-accepted by the women using them.
WHO releases the first integrated progress report on HIV, hepatitis and STIs
23 May 2019 – The new progress report being released today at the 72nd World Health Assembly reviews success and challenges in implementing the global health sector strategies, 2016-2021 on HIV, hepatitis and sexually transmitted infections (STIs). The report also outlines 8 joint actions for accelerating progress towards universal health coverage.
WHO Advisory Group of Women Living with HIV to meet in Geneva
After IAS 2019: what’s next?
Pushing for high-quality HIV services in low- and middle-income countries
Women and adolescent girls living with HIV need better advice and access to contraceptives
HIV and hepatitis news - September 2019
HIV topic: "treat all"
WHO HIV apps
More HIV apps
Towards UHC to end AIDS
WHO, Department of HIV
Sign-up for newsletters
Register in our Stakeholders’ database by sending an email to hiv-aids[at]who.int with subject line “Sign-up for newsletters”. You will receive regular updates from our Department.